Cargando…

FAM117A Is a New Prognostic Marker of Lung Adenocarcinoma and Predicts Sensitivity to PD0332991

Lung cancer is the second most common cancer and the leading cause for cancer mortality worldwide. Accelerated cell cycle progression is a well-characterized hallmark for cancer. The present study aims to identify biomarkers for clinical outcomes of lung cancer patients and their sensitivity to CDK...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Chao, Zhang, Jiajin, Wang, Kuan, Fan, Mengjiao, Hu, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913056/ https://www.ncbi.nlm.nih.gov/pubmed/35280504 http://dx.doi.org/10.1155/2022/3945446

Ejemplares similares

PD‐0332991 combined with cisplatin inhibits nonsmall cell lung cancer and reversal of cisplatin resistance
por: Liu, Minghui, et al.
Publicado: (2021)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

PD 0332991对人内皮细胞增殖和凋亡的作用
Publicado: (2018)

Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells
por: Wang, Daguang, et al.
Publicado: (2018)

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors
por: Liu, Minghui, et al.
Publicado: (2016)

Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
por: Bollard, Julien, et al.
Publicado: (2017)

Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Liu, Yu, et al.
Publicado: (2022)

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
por: Schwartz, G K, et al.
Publicado: (2011)

PD-0332991, a CDK4/6 Inhibitor, Significantly Prolongs Survival in a Genetically Engineered Mouse Model of Brainstem Glioma
por: Barton, Kelly L., et al.
Publicado: (2013)

Retracted: Expression of CDK6 in Stomach Cancer and the Effect of CDK4/6 Inhibitor PD-0332991 on the Function of Stomach Cancer Cells
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Effect of FAM196B in human lung adenocarcinoma
por: Feng, Yu, et al.
Publicado: (2018)

PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis
por: LI, CHUNSHENG, et al.
Publicado: (2014)

FAM83A and FAM83A-AS1 both play oncogenic roles in lung adenocarcinoma
por: Wang, Gaoming, et al.
Publicado: (2021)

Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma
por: Liu, Xin, et al.
Publicado: (2022)

AURKA and FAM83A are prognostic biomarkers and correlated with Tumor-infiltrating Lymphocytes in smoking related Lung Adenocarcinoma
por: Zhang, Mengyu, et al.
Publicado: (2021)

Long non-coding RNA FAM230B is a novel prognostic and diagnostic biomarker for lung adenocarcinoma
por: Cao, Yu, et al.
Publicado: (2022)

Dipeptidase‑2 is a prognostic marker in lung adenocarcinoma that is correlated with its sensitivity to cisplatin
por: Wang, Yuanyi, et al.
Publicado: (2023)

Occurrence of senescence-escaping cells in doxorubicin-induced senescence is enhanced by PD0332991, a cyclin-dependent kinase 4/6 inhibitor, in colon cancer HCT116 cells
por: Kitada, Kunio, et al.
Publicado: (2019)

FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1/NRF2 signaling pathway
por: Zhou, Yunjiang, et al.
Publicado: (2023)

FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma
por: Yu, Yilin, et al.
Publicado: (2021)

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
por: Finn, Richard S, et al.
Publicado: (2009)

Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma
por: Ma, Zuyi, et al.
Publicado: (2021)

FAM83H‐AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinoma
por: Wang, Siwei, et al.
Publicado: (2021)

Systematic Analysis of Gene Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma with a Case Study of FAM83A and FAM83B
por: Cai, Ling, et al.
Publicado: (2019)

LncRNA FAM83A‐AS1 promotes lung adenocarcinoma progression by enhancing the pre‐mRNA stability of FAM83A
por: Wang, Wenyi, et al.
Publicado: (2021)

FAM72 family proteins as poor prognostic markers in clear cell renal carcinoma
por: Gou, Hui, et al.
Publicado: (2023)

Single-particle isomeric states in 121Pd and 117Ru
por: Lalkovski, S., et al.
Publicado: (2011)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

Overexpression of Family with Sequence Similarity 83, Member A (FAM83A) Predicts Poor Clinical Outcomes in Lung Adenocarcinoma
por: Zhang, Jing-Tao, et al.
Publicado: (2019)

Pleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusion
por: Verma, Akash, et al.
Publicado: (2016)

Lysosome-related genes: A new prognostic marker for lung adenocarcinoma
por: Hu, Zeyang, et al.
Publicado: (2023)

FAM83A antisense RNA 1 (FAM83A-AS1) silencing impairs cell proliferation and induces autophagy via MET-AMPKɑ signaling in lung adenocarcinoma
por: Zhao, Huijie, et al.
Publicado: (2022)

FAM111B enhances proliferation of KRAS‐driven lung adenocarcinoma by degrading p16
por: Kawasaki, Keisuke, et al.
Publicado: (2020)

FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series.
por: Zhao, Liufang, et al.
Publicado: (2020)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019)

Identification of lncRNA FAM83H-AS1 as a novel prognostic marker in luminal subtype breast cancer
por: Yang, Fan, et al.
Publicado: (2016)

FAM111B, a direct target of p53, promotes the malignant process of lung adenocarcinoma
por: Sun, Haijun, et al.
Publicado: (2019)

Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis
por: Lu, Mingze, et al.
Publicado: (2021)

The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma
por: Guo, Chang-Ying, et al.
Publicado: (2019)

In silico analysis reveals PRR11 as a prognostic and oncogenic marker in lung adenocarcinoma
por: Hu, Ankang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0dnif6fsmgi85mlh1283ape382